Drug intelligence / Profile preview

ONM-423

Development stage: Preclinical
Lead developer: OncoNano Medicine, Inc.
Modality: Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

ONM-423 is an investigational polymer-drug conjugate (PDC) being developed by OncoNano Medicine for the treatment of solid tumors. Utilizing OncoNano's proprietary ON-BOARD™ ultra-pH sensitive micelle technology, ONM-423 is designed to encapsulate and shield a therapeutic payload (to be announced) during systemic circulation. Upon entering the acidic microenvironment characteristic of solid tumors, the polymeric micelle undergoes a rapid, pH-dependent transition to selectively release its payload directly at the tumor site. This mechanism aims to enhance the therapeutic index of the payload by maximizing anti-tumor efficacy while minimizing off-target systemic toxicities.

Beyond the preview

Go deeper on ONM-423.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONM-423.

Explore the full profile